» Articles » PMID: 28796095

Intracanalicular Vestibular Schwannomas: Initial Clinical Manifestation, Imaging Classification, and Risk Stratification for Management Proposal

Overview
Journal Otol Neurotol
Date 2017 Aug 11
PMID 28796095
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: There is no consensus about the use of observation as a therapeutic modality for intracanalicular vestibular schwannoma (ICVS). The objective of this study was to describe tumor evolution, its correlation with initial size, stage of vestibular schwannoma, clinical presentation and to propose a risk classification for tumor growth with a therapeutic decision algorithm.

Methods: Fifty-three patients with ICVS were followed prospectively from 2010 to 2015. The mean follow-up was 32 months. Patients underwent clinical examination, audiogram, magnetic resonance imaging at 6, 12, and then 12 months intervals within the first 5 years of initial diagnosis. We analyzed the patient's clinical course, audiologic changes, initial tumor location, and correlation of different parameters with ICVS growth.

Results: Fourteen patients (26%) deteriorated their hearing level and 17 patients (27%) showed tumor growth during the follow-up period. Growth was noted during the first year of observation in 13 patients (76.5%). Considering initial presentation: tumor size, intracanalicular staging, and hearing level, patients with larger vestibular schwannoma, extension to the fundus regardless of tumor size, higher initial pure-tone average, and speech recognition test showed a significantly higher rate of tumor growth. ICVS evolution was not correlated with hearing deterioration with time.

Discussion: We should consider observation a therapeutic modality. We valid the intrameatal staging as prognostic factor and propose a stratification of patients into low, moderate, or high risk for potential tumor growth to guide the initial management of ICVS.

Citing Articles

Management of sporadic intracanalicular vestibular schwannomas: A critical review and International Stereotactic Radiosurgery Society (ISRS) practice guidelines.

Balossier A, Sahgal A, Kotecha R, Fariselli L, Gorgulho A, Levivier M Neuro Oncol. 2023; 26(3):429-443.

PMID: 38134966 PMC: 10912008. DOI: 10.1093/neuonc/noad253.


Nanomedicine in Clinical Photodynamic Therapy for the Treatment of Brain Tumors.

Kim H, Lee D Biomedicines. 2022; 10(1).

PMID: 35052776 PMC: 8772938. DOI: 10.3390/biomedicines10010096.


Current Understanding of Hearing Loss in Sporadic Vestibular Schwannomas: A Systematic Review.

Gan J, Zhang Y, Wu J, Lei D, Zhang F, Zhao H Front Oncol. 2021; 11:687201.

PMID: 34476211 PMC: 8406761. DOI: 10.3389/fonc.2021.687201.


Development of a model to predict vestibular schwannoma growth: An opportunity to introduce new wait and scan strategies.

Hentschel M, Hannink G, Steens S, Mulder J, Rovers M, Kunst H Clin Otolaryngol. 2020; 46(1):273-283.

PMID: 33090707 PMC: 7821120. DOI: 10.1111/coa.13661.


Intracochlear Perfusion of Tumor Necrosis Factor-Alpha Induces Sensorineural Hearing Loss and Synaptic Degeneration in Guinea Pigs.

Katsumi S, Sahin M, Lewis R, Iyer J, Landegger L, Stankovic K Front Neurol. 2020; 10:1353.

PMID: 32116980 PMC: 7025643. DOI: 10.3389/fneur.2019.01353.